Liproxstatin-1

Cas No.:	950455-15-9
Chemical Name:	Liproxstatin-1
Synonyms:	Liproxstatin-1;N-[(3-Chlorophenyl)methyl]-spiro[piperidine-4,2′(1′H)-quinoxalin]-3′-amine;N-[(3-chlorophenyl)methyl]spiro[4H-quinoxaline-3,4′-piperidine]-2-amine;Liproxstatin 1;BCP15985;DNDI1417503;s7699;AK548157;J3.631.135E;N-(3-Chlorobenzyl)-1'H-spiro[piperidine-4,2'-quinoxalin]-3'-amine;N-(3-Chlorobenzyl)spiro[quinoxaline-2(1H),4'-piperidine]-3-amine;N-[(3-chlorophenyl)methyl]spiro[4H-quinoxaline-3,4'-piperidine]-2-amine;N-[(3-chlorophenyl)methyl]-1'H-spiro[piperidine-4,2'-quinoxa
SMILES:	ClC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])/N=C1/C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])N([H])C2=C([H])C([H])=C([H])C([H])=C2N/1[H]
Formula:	C19H21ClN4
M.Wt:	340.8498
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Liproxstatin-1 is a potent ferroptosis inhibitor, with IC50 of approximately 38 nM.
In Vivo:	Liproxstatin-1 (10 mg/kg, i.p.) suppresses ferroptosis in human cells, Gpx4−/− kidney and in an ischaemia/reperfusion-induced tissue injury model[1].
In Vitro:	Liproxstatin-1 prevents BODIPY 581/591 C11 oxidation in Gpx4−/− cells. Moreover, Liproxstatin-1 does not interfere with other classical types of cell death, such as TNFα-induced apoptosis and H2O2-induced necrosis, and in the bona fide L929 model of TNFα/zvad-induced necroptosis[1]. Liproxstatin-1 has great antiferroptotic activity with EC50 of appr 38 nM. Fer-1 and Liproxstatin-1 are inherently good, but not great, radical-trapping antioxidants, but they are excellent in phospholipid bilayers. Fer-1 (10 μM) and Liproxstatin-1 (10 μM) do not exhibit significant inhibitory activity in the 15-LOX-1 overexpressing cells, and the concentration is almost 1000-fold higher than their EC50s for subverting RSL3-induced ferroptosis in these cells (15 and 27 nM, respectively)[2].